2016-03-05T00:00:00.000-05:00
Exchange Commission,0.314329
strong buy rating,0.26133
Boston Advisors,0.440401
LGT Capital Partners,0.358648
business’s stock,-0.211095
PGGM Investments,0.295276
stock,0.129909
chief executive officer,0.228827
InvestorPlace Broker Center,0.555736
GILD shares,-0.314518
Janus Capital Management,0.109048
biopharmaceutical company,0.440686
equities analysts,-0.314518
personal trading style,0.598412
research-based biopharmaceutical company,0.642682
ex-dividend date,-0.378179
Gilead Sciences Inc.,0.555178
equities research analysts,-0.265003
average price,0.124482
consensus estimate,0.591789
shares,0.0673037
concise daily summary,0.447788
consensus target price,0.484136
Gilead Sciences,0.0845017
stock broker,0.245696
consensus rating,0.443743
John C. Martin,-0.211095
recent Form,0.314329
Verde Servico Internacionais,0.286687
chronic hepatitis,-0.646567
new stake,0.290981
quarter,0.0311397
